Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Apyx Medical (APYX) over the last 15 years, with Q3 2025 value amounting to $45000.0.

  • Apyx Medical's Cash from Financing Activities rose 100000.0% to $45000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year decrease of 7123.25%. This contributed to the annual value of $6.7 million for FY2024, which is 7903.07% down from last year.
  • Latest data reveals that Apyx Medical reported Cash from Financing Activities of $45000.0 as of Q3 2025, which was up 100000.0% from $25000.0 recorded in Q2 2025.
  • Apyx Medical's Cash from Financing Activities' 5-year high stood at $23.8 million during Q4 2023, with a 5-year trough of -$61000.0 in Q1 2021.
  • In the last 5 years, Apyx Medical's Cash from Financing Activities had a median value of $25000.0 in 2025 and averaged $2.1 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first crashed by 50666.67% in 2021, then surged by 23854000.0% in 2023.
  • Over the past 5 years, Apyx Medical's Cash from Financing Activities (Quarter) stood at -$39000.0 in 2021, then soared by 74.36% to -$10000.0 in 2022, then surged by 238540.0% to $23.8 million in 2023, then tumbled by 71.65% to $6.8 million in 2024, then tumbled by 99.33% to $45000.0 in 2025.
  • Its Cash from Financing Activities was $45000.0 in Q3 2025, compared to $25000.0 in Q2 2025 and $25000.0 in Q1 2025.